Socialstyrelsens riktlinjer - Svensk Kirurgisk Förening

38. Scheuer, L., N. Kauff, et al. (2002). “Outcome of preventive surgery and
screening for breast and ovarian cancer in BRCA mutation carriers.“ J Clin
Oncol 20(5):1260-8.
39. Tilanus-Linthorst, M. M., I. M. Obdeijn, et al. (2000). “First experiences in
screening women at high risk for breast cancer with MR imaging.” Breast
Cancer Res Treat 63(1):53-60.
40. Warner, E., D. B. Plewes, et al. (2001). “Comparison of breast magnetic resonance
imaging, mammography, and ultrasound for surveillance of women
at high risk for hereditary breast cancer.“ J Clin Oncol 19(15):3524-31.
41. Stoutjesdijk, M. J., C. Boetes, et al. (2001). “Magnetic resonance imaging
and mammography in women with a hereditary risk of breast cancer.” J Natl
Cancer Inst 93(14):1095-102.
42. Kuhl, C. K., S. Schrading, et al. (2005). “Mammography, breast ultrasound,
and magnetic resonance imaging for surveillance of women at high familial
risk for breast cancer.” J Clin Oncol 23(33):8469-76.
43. Meijers-Heijboer, H., B. van Geel, et al. (2001). “Breast cancer after prophylactic
bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.”
N Engl J Med 345(3):159-164.
44. Rebbeck, T. R., T. Friebel, et al. (2004). “Bilateral prophylactic mastectomy
reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the
PROSE Study Group.” J Clin Oncol 22(6):1055-62.
45. Schrag, D., K. M. Kuntz, et al. (1997). “Decision analysis – effects of prophylactic
mastectomy and oophorectomy on life expectancy among women
with BRCA1 or BRCA2 mutations.” N Engl J Med 336(20):1465-71.
46. van Roosmalen, M. S., L. C. Verhoef, et al. (2002). “Decision analysis of
prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent
role for oophorectomy.” J Clin Oncol 20(8):2092-100.
47. Hartmann, L. C., D. J. Schaid, et al. (1999). “Efficacy of bilateral prophylactic
mastectomy in women with a family history of breast cancer.“ N Engl J
Med 340(2):77-84.
48. Thompson, D. and D. F. Easton (2002). “Cancer Incidence in BRCA1 mutation
carriers.” J Natl Cancer Inst 94(18):1358-65.
49. Brose, M. S., T. R. Rebbeck, et al. (2002). “Cancer risk estimates for BRCA1
mutation carriers identified in a risk evaluation program.” J Natl Cancer Inst
94(18):1365-72.
50. Kauff, N. D., J. M. Satagopan, et al. (2002). “Risk-reducing salpingo-oophorectomy
in women with a BRCA1 or BRCA2 mutation.” N Engl J Med
346(21):1609-15.
51. Rebbeck, T. R., H. T. Lynch, et al. (2002). “Prophylactic oophorectomy in
carriers of BRCA1 or BRCA2 mutations.” N Engl J Med 346(21):1616-22.
4